Experienced in Aphthous Stomatitis

Yutaka Kawano

Tokushima, JP 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Aphthous Stomatitis
Tokushima, JP 
OverviewLocationsClinical Research

Overview

Yutaka Kawano practices in Tokushima, Japan. Mr. Kawano is rated as an Experienced expert by MediFind in the treatment of Aphthous Stomatitis. His top areas of expertise are Prolidase Deficiency, Juvenile Dermatomyositis, Non-Alcoholic Fatty Liver Disease, Mouth Sores, and Tissue Biopsy.

His clinical research consists of co-authoring 81 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Aphthous Stomatitis.

Gender
Male

Locations

Tokushima, 7708503, Japan
Other Locations
Saitama, Japan
Ishikari, 0610293, Japan
Shintoshin, 3308777, Japan
Sapporo, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Recruiting
Publish Date: September 23, 2025
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Completed
Publish Date: October 07, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
View 1 Less Clinical Trial

81 Total Publications

Pemafibrate Ameliorates Steatotic Liver Disease Regardless of Endothelial Dysfunction in Mice.
Pemafibrate Ameliorates Steatotic Liver Disease Regardless of Endothelial Dysfunction in Mice.
Journal: Antioxidants (Basel, Switzerland)
Published: June 07, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Kawano's expertise for a condition
ConditionClose
        View All 49 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile